In the latest attempt to attack the cost of hepatitis C drugs, an advocacy group is challenging several U.S. patents for the Sovaldi treatment that is sold by Gilead Sciences (GILD).

The group wants to overturn six patents for the drug, which is the oldest of several Gilead hepatitis C medicines, in hopes of spurring lower-cost generic versions to become available sooner than might otherwise be possible. The group contended that U.S. taxpayers can save $10 billion and generics can get to market 14 years faster if it succeeds.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy